Open AccessO-GlcNAcase Inhibitor ASN90 is a Multimodal Drug Candidate for Tau and α-Synuclein Proteinopathies
Author(s) -
Bruno Permanne,
Astrid Sand,
Solenne Ousson,
Maud Nény,
Jennifer Hantson,
Ryan Schubert,
Christoph Wießner,
Anna Quattropani,
Dirk Beher
Publication year - 2022
Publication title -
acs chemical neuroscience
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.158
H-Index - 69
ISSN - 1948-7193
DOI - 10.1021/acschemneuro.2c00057
Subject(s) - tauopathy , synucleinopathies , drug discovery , intracellular , neuroscience , astrogliosis , tau protein , pharmacology , alpha synuclein , drug development , neurodegeneration , biology , chemistry , microbiology and biotechnology , parkinson's disease , biochemistry , alzheimer's disease , drug , medicine , pathology , disease , central nervous system
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom